Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO
Phase of Trial: Phase IV
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms IMPRES
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 Planned initiation date changed from 1 Jul 2017 to 10 Aug 2017.
- 19 Jun 2017 New trial record